SCHEMBL6866219

SCHEMBL6866219

CCCCCC(=O)NS(=O)(=O)c1ccccc1NC(=O)c1ccccc1C#Cc1ccc(C(F)(F)F)cc1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
RXFP1 Q9HBX9 3/20 0.43
HDAC3 O15379 1/20 0.36
HDAC1 Q13547 1/20 0.36
KCNA5 P22460 1/20 0.36
TSHR P16473 1/20 0.36
PLK1 P53350 4/20 0.35
ALDH1A1 P00352 1/20 0.35
MAPT P10636 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
PTPN1 P18031 1/20 0.35
CA12 O43570 1/20 0.35
CA9 Q16790 1/20 0.35
PTGES2 Q9H7Z7 1/20 0.35
PLK3 Q9H4B4 3/20 0.35
KCNQ3 O43525 1/20 0.35
KCNQ2 O43526 1/20 0.35
KCNQ4 P56696 1/20 0.35
KCNQ5 Q9NR82 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6864874 0.91 RXFP1 (0.37) RXFP1HDAC3HDAC1KCNA5ALDH1A1
SCHEMBL6860195 0.90 TSHR (0.38) RXFP1HDAC3HDAC1TSHRALDH1A1
SCHEMBL6864851 0.89 HDAC3 (0.38) RXFP1HDAC3HDAC1TSHRPLK1
SCHEMBL6860345 0.86 KCNA5 (0.35) RXFP1KCNA5PTGES2
SCHEMBL7048492 0.81 PTGES (0.50) PLK1SMN1; SMN2PLK3
SCHEMBL6866204 0.81 FFAR1 (0.38) HDAC3HDAC1TSHRALDH1A1
SCHEMBL6864455 0.81 ACACB (0.38) HDAC3HDAC1ALDH1A1MAPT
SCHEMBL7051034 0.81 PTGES (0.49) PLK1SMN1; SMN2PLK3
SCHEMBL6866217 0.80 PLK1 (0.41) HDAC1PLK1ALDH1A1MAPTSMN1; SMN2
SCHEMBL6866357 0.79 CA2 (0.51) RXFP1SMN1; SMN2CA12CA9PTGES2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6812252-B2 ACYLSULFONAMIDE DERIVATIVES CONTAINING FLUOROSUBSTITUTEDPHENYLETHYNYL GROUP HAVING A HYPOGLYCEMIC EFFECT AND FREE OF THE SIDE EFFECT AJINOMOTO CO., INC. (JP) 2004-11-02 US disclosed
US-20030191323-A1 Hypoglycemic agent AJINOMOTO CO., INC. (JP) 2003-10-09 US disclosed
US-20030181764-A1 Acylsulfonamide derivatives AJINOMOTO CO. INC (JP) 2003-09-25 US disclosed
EP-1316548-A1 ACYLSULFONAMIDE DERIVATIVES Ajinomoto Co., Inc. (JP) 2003-06-04 EP disclosed
EP-1300142-A1 HYPOGLYCEMICS Ajinomoto Co., Inc. (JP) 2003-04-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030181764-A1 Acylsulfonamide derivatives DPP4, SLC5A2, GLP1R RXFP1 3201/4885HDAC3 33/4885HDAC1 172/4885
US-20030191323-A1 Hypoglycemic agent GPR119, IAPP, SLC5A2 RXFP1 2336/4885HDAC3 207/4885HDAC1 305/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.